25 XP   0   0   10

Vivoryon Therapeutics NV
Buy, Hold or Sell?

Let's analyse Vivoryon together

PenkeI guess you are interested in Vivoryon Therapeutics NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Vivoryon Therapeutics NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Vivoryon Therapeutics NV

I send you an email if I find something interesting about Vivoryon Therapeutics NV.

Quick analysis of Vivoryon (30 sec.)










What can you expect buying and holding a share of Vivoryon? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
‚ā¨1.01
Expected worth in 1 year
‚ā¨0.97
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
‚ā¨-0.03
Return On Investment
-1.6%

For what price can you sell your share?

Current Price per Share
‚ā¨2.17
Expected price per share
‚ā¨0.73 - ‚ā¨6.82
How sure are you?
50%

1. Valuation of Vivoryon (5 min.)




Live pricePrice per Share (EOD)

‚ā¨2.17

Intrinsic Value Per Share

‚ā¨-11.44 - ‚ā¨-4.98

Total Value Per Share

‚ā¨-10.43 - ‚ā¨-3.98

2. Growth of Vivoryon (5 min.)




Is Vivoryon growing?

Current yearPrevious yearGrowGrow %
How rich?$28.1m$28.3m-$239.8k-0.9%

How much money is Vivoryon making?

Current yearPrevious yearGrowGrow %
Making money-$30.3m-$30.1m-$199.1k-0.7%
Net Profit Margin782.9%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Vivoryon (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#521 / 991

Most Revenue
#988 / 991

Most Profit
#811 / 991

What can you expect buying and holding a share of Vivoryon? (5 min.)

Welcome investor! Vivoryon's management wants to use your money to grow the business. In return you get a share of Vivoryon.

What can you expect buying and holding a share of Vivoryon?

First you should know what it really means to hold a share of Vivoryon. And how you can make/lose money.

Speculation

The Price per Share of Vivoryon is ‚ā¨2.17. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Vivoryon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Vivoryon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨1.01. Based on the TTM, the Book Value Change Per Share is ‚ā¨-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨0.38 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Vivoryon.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps-1.16-53.7%-1.16-53.7%-1.16-53.3%-0.77-35.4%-0.56-25.9%
Usd Book Value Change Per Share-0.01-0.4%-0.01-0.4%0.4118.8%0.2210.0%0.135.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-0.4%-0.01-0.4%0.4118.8%0.2210.0%0.135.8%
Usd Price Per Share8.72-8.72-11.05-11.12-13.57-
Price to Earnings Ratio-7.49--7.49--9.55--17.71--4,385.87-
Price-to-Total Gains Ratio-947.21--947.21-27.04--196.48-582,834.02-
Price to Book Ratio8.07-8.07-10.15-12.08-18,480.37-
Price-to-Total Gains Ratio-947.21--947.21-27.04--196.48-582,834.02-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.323853
Number of shares430
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.22
Usd Total Gains Per Share-0.010.22
Gains per Quarter (430 shares)-3.9692.85
Gains per Year (430 shares)-15.83371.41
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-16-260371361
20-32-420743732
30-47-58011141103
40-63-74014861474
50-79-90018571845
60-95-106022282216
70-111-122026002587
80-127-138029712958
90-142-154033433329
100-158-170037143700

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.013.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%6.07.00.046.2%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.013.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%6.07.00.046.2%

Fundamentals of Vivoryon

About Vivoryon Therapeutics NV

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

Fundamental data was last updated by Penke on 2024-05-26 03:15:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Vivoryon Therapeutics NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Vivoryon earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Vivoryon to the¬†Biotechnology industry mean.
  • A Net Profit Margin of 782.9%¬†means that¬†€7.83 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vivoryon Therapeutics NV:

  • The MRQ is 782.9%. The company is making a huge profit. +2
  • The TTM is 782.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ782.9%TTM782.9%0.0%
TTM782.9%YOY-+782.9%
TTM782.9%5Y133.1%+649.9%
5Y133.1%10Y66.5%+66.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ782.9%-178.5%+961.4%
TTM782.9%-223.7%+1,006.6%
YOY--245.1%+245.1%
5Y133.1%-390.8%+523.9%
10Y66.5%-503.2%+569.7%
1.1.2. Return on Assets

Shows how efficient Vivoryon is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Vivoryon to the¬†Biotechnology industry mean.
  • -91.9% Return on Assets means that¬†Vivoryon generated¬†€-0.92 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vivoryon Therapeutics NV:

  • The MRQ is -91.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -91.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-91.9%TTM-91.9%0.0%
TTM-91.9%YOY-89.7%-2.2%
TTM-91.9%5Y-61.2%-30.8%
5Y-61.2%10Y-38,978.0%+38,916.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-91.9%-11.6%-80.3%
TTM-91.9%-11.6%-80.3%
YOY-89.7%-10.9%-78.8%
5Y-61.2%-12.9%-48.3%
10Y-38,978.0%-14.1%-38,963.9%
1.1.3. Return on Equity

Shows how efficient Vivoryon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Vivoryon to the¬†Biotechnology industry mean.
  • -107.8% Return on Equity means Vivoryon generated €-1.08¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vivoryon Therapeutics NV:

  • The MRQ is -107.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -107.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-107.8%TTM-107.8%0.0%
TTM-107.8%YOY-106.2%-1.6%
TTM-107.8%5Y-74.4%-33.5%
5Y-74.4%10Y-88,776.0%+88,701.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-107.8%-13.9%-93.9%
TTM-107.8%-14.9%-92.9%
YOY-106.2%-13.5%-92.7%
5Y-74.4%-18.2%-56.2%
10Y-88,776.0%-19.0%-88,757.0%

1.2. Operating Efficiency of Vivoryon Therapeutics NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Vivoryon is operating .

  • Measures how much profit Vivoryon makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Vivoryon to the¬†Biotechnology industry mean.
  • An Operating Margin of 0.0%¬†means the company generated €0.00 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-23.8%+23.8%
5Y-23.8%10Y-11.9%-11.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--344.0%+344.0%
TTM--235.7%+235.7%
YOY--262.3%+262.3%
5Y-23.8%-383.7%+359.9%
10Y-11.9%-485.1%+473.2%
1.2.2. Operating Ratio

Measures how efficient Vivoryon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Biotechnology industry mean).
  • An Operation Ratio of -6.81 means that the operating costs are €-6.81 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is -6.809.
  • The TTM is -6.809.
Trends
Current periodCompared to+/- 
MRQ-6.809TTM-6.8090.000
TTM-6.809YOY--6.809
TTM-6.8095Y-0.924-5.885
5Y-0.92410Y-0.462-0.462
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.8093.092-9.901
TTM-6.8093.353-10.162
YOY-3.564-3.564
5Y-0.9244.836-5.760
10Y-0.4626.187-6.649

1.3. Liquidity of Vivoryon Therapeutics NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Vivoryon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Biotechnology industry mean).
  • A Current Ratio of 9.37¬†means the company has €9.37 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 9.369. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.369. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.369TTM9.3690.000
TTM9.369YOY9.401-0.032
TTM9.3695Y18.660-9.291
5Y18.66010Y12.683+5.977
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.3693.776+5.593
TTM9.3694.034+5.335
YOY9.4014.978+4.423
5Y18.6605.984+12.676
10Y12.6836.360+6.323
1.3.2. Quick Ratio

Measures if Vivoryon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Vivoryon to the¬†Biotechnology industry mean.
  • A Quick Ratio of 3.15¬†means the company can pay off €3.15 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 3.149. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.149. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.149TTM3.1490.000
TTM3.149YOY9.350-6.200
TTM3.1495Y16.266-13.117
5Y16.26610Y35.690-19.424
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1493.198-0.049
TTM3.1493.631-0.482
YOY9.3504.843+4.507
5Y16.2665.825+10.441
10Y35.6906.378+29.312

1.4. Solvency of Vivoryon Therapeutics NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Vivoryon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Vivoryon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15¬†means that Vivoryon assets are¬†financed with 14.7% credit (debt) and the remaining percentage (100% - 14.7%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.147. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.147. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.147TTM0.1470.000
TTM0.147YOY0.155-0.008
TTM0.1475Y0.163-0.016
5Y0.16310Y0.247-0.084
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1470.336-0.189
TTM0.1470.346-0.199
YOY0.1550.284-0.129
5Y0.1630.367-0.204
10Y0.2470.376-0.129
1.4.2. Debt to Equity Ratio

Measures if Vivoryon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Vivoryon to the¬†Biotechnology industry mean.
  • A Debt to Equity ratio of 17.3% means that company has €0.17 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.173. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.173. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.173TTM0.1730.000
TTM0.173YOY0.184-0.011
TTM0.1735Y0.209-0.036
5Y0.20910Y0.461-0.252
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1730.382-0.209
TTM0.1730.421-0.248
YOY0.1840.371-0.187
5Y0.2090.447-0.238
10Y0.4610.476-0.015

2. Market Valuation of Vivoryon Therapeutics NV

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Vivoryon generates.

  • Above 15 is considered overpriced but¬†always compare¬†Vivoryon to the¬†Biotechnology industry mean.
  • A PE ratio of -7.49 means the investor is paying €-7.49¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vivoryon Therapeutics NV:

  • The EOD is -1.996. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.487. Based on the earnings, the company is expensive. -2
  • The TTM is -7.487. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.996MRQ-7.487+5.491
MRQ-7.487TTM-7.4870.000
TTM-7.487YOY-9.554+2.068
TTM-7.4875Y-17.706+10.219
5Y-17.70610Y-4,385.875+4,368.169
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.996-2.473+0.477
MRQ-7.487-2.865-4.622
TTM-7.487-2.837-4.650
YOY-9.554-3.461-6.093
5Y-17.706-6.135-11.571
10Y-4,385.875-6.468-4,379.407
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Vivoryon Therapeutics NV:

  • The EOD is -2.565. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.621. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.621. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.565MRQ-9.621+7.056
MRQ-9.621TTM-9.6210.000
TTM-9.621YOY-12.336+2.715
TTM-9.6215Y-18.808+9.187
5Y-18.80810Y-16,750.360+16,731.552
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.565-3.046+0.481
MRQ-9.621-3.513-6.108
TTM-9.621-3.609-6.012
YOY-12.336-4.805-7.531
5Y-18.808-7.882-10.926
10Y-16,750.360-8.502-16,741.858
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Vivoryon is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Biotechnology industry mean).
  • A PB ratio of 8.07 means the investor is paying €8.07¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Vivoryon Therapeutics NV:

  • The EOD is 2.152. Based on the equity, the company is underpriced. +1
  • The MRQ is 8.073. Based on the equity, the company is overpriced. -1
  • The TTM is 8.073. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD2.152MRQ8.073-5.921
MRQ8.073TTM8.0730.000
TTM8.073YOY10.149-2.076
TTM8.0735Y12.083-4.010
5Y12.08310Y18,480.373-18,468.289
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.1522.012+0.140
MRQ8.0732.185+5.888
TTM8.0732.227+5.846
YOY10.1492.447+7.702
5Y12.0833.726+8.357
10Y18,480.3734.199+18,476.174
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Vivoryon Therapeutics NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.009-0.0090%0.382-102%0.202-104%0.117-107%
Book Value Per Share--1.0081.0080%1.017-1%1.061-5%0.531+90%
Current Ratio--9.3699.3690%9.4010%18.660-50%12.683-26%
Debt To Asset Ratio--0.1470.1470%0.155-5%0.163-10%0.247-40%
Debt To Equity Ratio--0.1730.1730%0.184-6%0.209-17%0.461-62%
Dividend Per Share----0%-0%-0%-0%
Eps---1.087-1.0870%-1.080-1%-0.717-34%-0.524-52%
Free Cash Flow Per Share---0.846-0.8460%-0.837-1%-0.625-26%-0.313-63%
Free Cash Flow To Equity Per Share---0.846-0.8460%0.444-291%0.003-30395%0.191-544%
Gross Profit Margin--1.0001.0000%1.310-24%1.238-19%1.230-19%
Intrinsic Value_10Y_max---4.983--------
Intrinsic Value_10Y_min---11.443--------
Intrinsic Value_1Y_max---0.354--------
Intrinsic Value_1Y_min---0.825--------
Intrinsic Value_3Y_max---1.174--------
Intrinsic Value_3Y_min---2.772--------
Intrinsic Value_5Y_max---2.128--------
Intrinsic Value_5Y_min---5.025--------
Market Cap56564956.000-275%212183817.120212183817.1200%269009376.000-21%270625530.624-22%330370629.712-36%
Net Profit Margin--7.8297.8290%-+100%1.331+488%0.665+1077%
Operating Margin----0%-0%-0.2380%-0.1190%
Operating Ratio---6.809-6.8090%--100%-0.924-86%-0.462-93%
Pb Ratio2.152-275%8.0738.0730%10.149-20%12.083-33%18480.373-100%
Pe Ratio-1.996+73%-7.487-7.4870%-9.554+28%-17.706+137%-4385.875+58483%
Price Per Share2.170-275%8.1408.1400%10.320-21%10.382-22%12.674-36%
Price To Free Cash Flow Ratio-2.565+73%-9.621-9.6210%-12.336+28%-18.808+95%-16750.360+174008%
Price To Total Gains Ratio-252.513+73%-947.215-947.2150%27.039-3603%-196.477-79%582834.024-100%
Quick Ratio--3.1493.1490%9.350-66%16.266-81%35.690-91%
Return On Assets---0.919-0.9190%-0.897-2%-0.612-33%-389.780+42298%
Return On Equity---1.078-1.0780%-1.062-1%-0.744-31%-887.760+82223%
Total Gains Per Share---0.009-0.0090%0.382-102%0.202-104%0.117-107%
Usd Book Value--28145393.80028145393.8000%28385275.400-1%29606315.580-5%14809436.798+90%
Usd Book Value Change Per Share---0.009-0.0090%0.409-102%0.216-104%0.125-107%
Usd Book Value Per Share--1.0801.0800%1.089-1%1.136-5%0.568+90%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.164-1.1640%-1.157-1%-0.768-34%-0.561-52%
Usd Free Cash Flow---23618699.500-23618699.5000%-23353116.300-1%-17445817.720-26%-8728813.803-63%
Usd Free Cash Flow Per Share---0.906-0.9060%-0.896-1%-0.669-26%-0.335-63%
Usd Free Cash Flow To Equity Per Share---0.906-0.9060%0.475-291%0.003-30395%0.204-544%
Usd Market Cap60575411.380-275%227227649.754227227649.7540%288082140.758-21%289812880.745-22%353793907.359-36%
Usd Price Per Share2.324-275%8.7178.7170%11.052-21%11.118-22%13.573-36%
Usd Profit---30351447.800-30351447.8000%-30152260.400-1%-20022831.480-34%-14632717.308-52%
Usd Revenue---3876658.000-3876658.0000%--100%1530101.920-353%765050.960-607%
Usd Total Gains Per Share---0.009-0.0090%0.409-102%0.216-104%0.125-107%
 EOD+3 -5MRQTTM+0 -0YOY+6 -275Y+6 -2710Y+11 -22

3.2. Fundamental Score

Let's check the fundamental score of Vivoryon Therapeutics NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.996
Price to Book Ratio (EOD)Between0-12.152
Net Profit Margin (MRQ)Greater than07.829
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.149
Current Ratio (MRQ)Greater than19.369
Debt to Asset Ratio (MRQ)Less than10.147
Debt to Equity Ratio (MRQ)Less than10.173
Return on Equity (MRQ)Greater than0.15-1.078
Return on Assets (MRQ)Greater than0.05-0.919
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Vivoryon Therapeutics NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.344
Ma 20Greater thanMa 502.257
Ma 50Greater thanMa 1001.301
Ma 100Greater thanMa 2003.274
OpenGreater thanClose2.160
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Cost of Revenue  88581461,5881,734-1,573161-686-525



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets30,829
Total Liabilities4,547
Total Stockholder Equity26,282
 As reported
Total Liabilities 4,547
Total Stockholder Equity+ 26,282
Total Assets = 30,829

Assets

Total Assets30,829
Total Current Assets29,812
Long-term Assets1,017
Total Current Assets
Cash And Cash Equivalents 18,562
Short-term Investments 10,021
Total Current Assets  (as reported)29,812
Total Current Assets  (calculated)28,583
+/- 1,229
Long-term Assets
Property Plant Equipment 76
Intangible Assets 941
Long-term Assets  (as reported)1,017
Long-term Assets  (calculated)1,017
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities3,182
Long-term Liabilities1,365
Total Stockholder Equity26,282
Total Current Liabilities
Accounts payable 2,894
Other Current Liabilities 1
Total Current Liabilities  (as reported)3,182
Total Current Liabilities  (calculated)2,895
+/- 287
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt38
Long-term Liabilities  (as reported)1,365
Long-term Liabilities  (calculated)38
+/- 1,327
Total Stockholder Equity
Total Stockholder Equity (as reported)26,282
Total Stockholder Equity (calculated)0
+/- 26,282
Other
Capital Stock26,067
Common Stock Shares Outstanding 26,067
Net Invested Capital 26,282
Net Working Capital 26,630
Property Plant and Equipment Gross 743



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
> Total Assets 
15,966
19,093
10,005
6,374
21
22
22
11
4
45,861
29,751
24,520
31,378
30,829
30,82931,37824,52029,75145,8614112222216,37410,00519,09315,966
   > Total Current Assets 
7,590
11,032
9,009
5,949
21
22
22
11
4
45,377
28,793
20,229
30,694
29,812
29,81230,69420,22928,79345,3774112222215,9499,00911,0327,590
       Cash And Cash Equivalents 
6,061
9,295
7,726
4,879
21
21
22
10
4
41,524
26,306
14,661
26,555
18,562
18,56226,55514,66126,30641,5244102221214,8797,7269,2956,061
       Short-term Investments 
27
1,028
2
186
101
0
0
0
0
0
21
7
7
10,021
10,02177210000010118621,02827
       Net Receivables 
0
0
0
0
0
125
166
46
91
602
129
3,360
3,965
0
03,9653,360129602914616612500000
       Inventory 
42
18
18
0
0
-125
-166
-46
-91
0
0
0
0
0
00000-91-46-166-12500181842
   > Long-term Assets 
8,376
8,061
996
425
0
0
0
0
0
484
958
4,291
684
1,017
1,0176844,291958484000004259968,0618,376
       Property Plant Equipment 
1,549
1,264
926
321
0
0
0
0
0
465
390
285
176
76
76176285390465000003219261,2641,549
       Goodwill 
1,996
1,996
0
0
0
0
0
0
0
0
0
0
0
0
0000000000001,9961,996
       Intangible Assets 
4,828
4,798
67
101
0
0
0
0
0
16
565
533
494
941
9414945335651600000101674,7984,828
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
3,473
14
0
0143,47300000000000
> Total Liabilities 
3,727
4,148
4,640
10,598
6
6
6
2
3
3,196
3,530
7,963
4,872
4,547
4,5474,8727,9633,5303,1963266610,5984,6404,1483,727
   > Total Current Liabilities 
3,090
3,136
3,570
9,333
5
5
5
1
1
930
1,325
5,051
3,265
3,182
3,1823,2655,0511,325930115559,3333,5703,1363,090
       Short-term Debt 
0
0
0
5,346
0
0
0
0
83
91
90
92
94
0
0949290918300005,346000
       Accounts payable 
938
1,215
731
1,327
1
2
2
0
1
1
1
4
3
2,894
2,8943411102211,3277311,215938
       Other Current Liabilities 
2,152
1,921
2,839
24
4
3
3
0
0
839
1,235
4,959
3,171
1
13,1714,9591,23583900334242,8391,9212,152
   > Long-term Liabilities 
637
1,012
1,070
1,265
929
822
850
1,171
1,854
2,266
2,205
2,912
1,607
1,365
1,3651,6072,9122,2052,2661,8541,1718508229291,2651,0701,012637
       Other Liabilities 
0
0
0
0
0
0
850
1,171
1,854
1,951
1,981
2,780
1,569
0
01,5692,7801,9811,9511,8541,171850000000
> Total Stockholder Equity
12,239
14,945
5,365
-4,224
16
16
16
9
1
42,665
26,221
16,557
26,506
26,282
26,28226,50616,55726,22142,66519161616-4,2245,36514,94512,239
   Common Stock
15,718
22,694
25,529
25,529
7
7
8
8
8
19,975
19,975
20,050
24,105
0
024,10520,05019,97519,9758887725,52925,52922,69415,718
   Retained Earnings -148,799-120,457-92,300-79,646-63,136-55-48-40-26-12-81,745-71,816-53,096-36,789
   Capital Surplus 00000000000000
   Treasury Stock00000000000000
   Other Stockholders Equity 
33,310
45,347
51,652
51,992
22
34
48
48
48
86,388
86,547
89,379
123,038
0
0123,03889,37986,54786,388484848342251,99251,65245,34733,310



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue-3,620
Cost of Revenue--525
Gross Profit-3,095-3,095
 
Operating Income (+$)
Gross Profit-3,095
Operating Expense-25,175
Operating Income-28,795-28,270
 
Operating Expense (+$)
Research Development17,637
Selling General Administrative3,272
Selling And Marketing Expenses0
Operating Expense25,17520,909
 
Net Interest Income (+$)
Interest Income478
Interest Expense-56
Other Finance Cost-0
Net Interest Income422
 
Pretax Income (+$)
Operating Income-28,795
Net Interest Income422
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-28,576-28,795
EBIT - interestExpense = -56
-28,342
-28,286
Interest Expense56
Earnings Before Interest and Taxes (EBIT)0-28,520
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-28,576
Tax Provision--234
Net Income From Continuing Ops-28,342-28,342
Net Income-28,342
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-422
 

Technical Analysis of Vivoryon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Vivoryon. The general trend of Vivoryon is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Vivoryon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Vivoryon Therapeutics NV.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.3 < 6.4 < 6.82.

The bearish price targets are: 0.999 > 0.92 > 0.73.

Tweet this
Vivoryon Therapeutics NV Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging¬†trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Vivoryon Therapeutics NV. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Vivoryon Therapeutics NV Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a¬†lagging momentum¬†indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Vivoryon Therapeutics NV. The current macd is 0.29775579.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vivoryon price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Vivoryon. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Vivoryon price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Vivoryon Therapeutics NV Daily Moving Average Convergence/Divergence (MACD) ChartVivoryon Therapeutics NV Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Vivoryon Therapeutics NV. The current adx is 55.09.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Vivoryon shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Vivoryon Therapeutics NV Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows¬†the current trend.
  • Shows¬†potential entry signals.
  • Shows¬†¬†potential exit signals.
  • Can be used to place¬†trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Vivoryon Therapeutics NV. The current sar is 5.49569143.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Vivoryon Therapeutics NV Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum¬†indicator, meaning the signals are instant.
  • Ranges¬†between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Vivoryon Therapeutics NV. The current rsi is 52.34. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
Vivoryon Therapeutics NV Daily Relative Strength Index (RSI) ChartVivoryon Therapeutics NV Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading¬†momentum¬†indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges¬†between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Vivoryon Therapeutics NV. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vivoryon price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Vivoryon Therapeutics NV Daily Stochastic Oscillator ChartVivoryon Therapeutics NV Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,¬†the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Vivoryon Therapeutics NV. The current cci is -13.39616459.

Vivoryon Therapeutics NV Daily Commodity Channel Index (CCI) ChartVivoryon Therapeutics NV Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Vivoryon Therapeutics NV. The current cmo is -3.84749325.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Vivoryon Therapeutics NV Daily Chande Momentum Oscillator (CMO) ChartVivoryon Therapeutics NV Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and¬†-100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Vivoryon Therapeutics NV. The current willr is -93.14388814.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Vivoryon Therapeutics NV Daily Williams %R ChartVivoryon Therapeutics NV Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold¬†

Score

Let's take a look at the Bollinger Bands of Vivoryon Therapeutics NV.

Vivoryon Therapeutics NV Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Vivoryon Therapeutics NV. The current atr is 0.45371602.

Vivoryon Therapeutics NV Daily Average True Range (ATR) ChartVivoryon Therapeutics NV Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Vivoryon Therapeutics NV. The current obv is -9,873,355.

Vivoryon Therapeutics NV Daily On-Balance Volume (OBV) ChartVivoryon Therapeutics NV Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Vivoryon Therapeutics NV. The current mfi is 25.53.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Vivoryon Therapeutics NV Daily Money Flow Index (MFI) ChartVivoryon Therapeutics NV Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Vivoryon Therapeutics NV.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-01-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI